New GSK shingles vaccine may challenge Merck after strong test data

LONDON (Reuters) - An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group's expanding vaccine unit a potential $1 billion boost.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news